Can a 'female Viagra' help breast cancer survivors regain desire?

NCT ID NCT03707340

Ongoing Symptom relief Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether flibanserin, a drug for low sexual desire, can be safely taken by breast cancer survivors who are on tamoxifen or similar hormone therapies. About 43 women with a history of breast cancer and no current disease will take flibanserin for 24 weeks. The main goal is to see how many women stop the drug due to side effects or other issues, and to check for any safety problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hypoactive sexual desire disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER HYPOSEXUAL DESIRE DISORDER

Contacts and locations

Locations

Memorial Sloan - Kettering Cancer Center

New York, New York, 10021, United States
Memorial Sloan Kettering Basking Ridge

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Cancer Center @ Commack

Commack, New York, 11725, United States
Memorial Sloan Kettering Monmouth

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau

Uniondale, New York, 11553, United States
Memorial Sloan Kettering Westchester

Harrison, New York, 10604, United States
Norwalk Hospital

Norwalk, Connecticut, 06850, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.